| Aug 1 |
Valneva and LimmaTech partner for shigellosis vaccine development
|
| Aug 1 |
Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate
|
| Jul 29 |
3 Promising Biotech Stocks You Can Pick Up for Less Than $10
|
| Jul 26 |
Can Valneva (VALN) Climb 149.04% to Reach the Level Wall Street Analysts Expect?
|
| Jul 22 |
Valneva and CEPI expand deal for chikungunya vaccine trials
|
| Jul 22 |
CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine
|
| Jul 18 |
Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026
|
| Jul 17 |
Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion
|
| Jul 4 |
Declaration of shares and voting rights - Valneva SE - June 30, 2024
|
| Jul 1 |
Valneva’s chikungunya vaccine gains EC’s market authorisation
|
